Eli Lilly's stock tumbled 8% on Tuesday after it forecast fourth-quarter sales of weight-loss drug Zepbound below Wall Street ...

The results are an uncomfortable echo of late October 2024, when Mounjaro and Zepbound missed by similar margins. Those ...

Eli Lilly has revised its revenue forecast for 2024 after seeing weaker-than-expected growth for its diabetes and obesity ...

The updated guidance, which was largely driven by lower-than-anticipated sales of GLP-1 blockbusters Mounjaro and Zepbound, ...

The weight-loss drug Zepbound (tirzepatide) now has another major benefit: on Dec. 20, it became the first drug approved by the U.S. Food and Drug Administration (FDA) to treat obstructive sleep ...

Ro integrates Eli Lilly’s Zepbound single-dose vials into its platform, offering obesity treatment starting at $399/month. Patients receive diagnosis, prescription, and home delivery through an ...

Dec 20 (Reuters) - The U.S. Food and Drug Administration on Friday approved Eli Lilly's (LLY.N), opens new tab weight-loss treatment, Zepbound, for obstructive sleep apnea, making it the first ...

The Phase IIIb SURMOUNT-5 trial found that Eli Lilly’s Zepbound was more effective in promoting weight loss than Novo Nordisk’s Wegovy. Credit: Ciara Kimsey / Shutterstock. Following positive results ...

The FDA has approved Eli Lilly’s obesity treatment, Zepbound, for the management of moderate to severe obstructive sleep apnea in people with obesity. This marks the first time a medication has been ...

Following positive results from its SURMOUNT-5 trial, Eli Lilly’s Zepbound (tirzepatide) will surpass Novo Nordisk’s Weogvy (semaglutide) in the obesity treatment market, according to a ...